-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4633 Evaluation of the Human Factor IX Gene Therapy Vector TAK-748 in Hemophilia: Results from Non-Clinical Studies in Factor IX Knockout Mice and Rhesus Monkeys

Program: Oral and Poster Abstracts
Session: 801. Gene Therapy and Transfer: Poster III
Hematology Disease Topics & Pathways:
Diseases, Bleeding and clotting
Monday, December 9, 2019, 6:00 PM-8:00 PM
Hall B, Level 2 (Orange County Convention Center)

Markus Weiller1*, Helen Wang2*, Sogué Coulibaly1*, Maria Schuster1*, Hanspeter Rottensteiner1*, Kefeng Sun2*, Marinee K Chuah3,4*, Thierry Vandendriessche3,4*, Friedrich Scheiflinger1* and Werner Höllriegl1

1Baxalta Innovations GmbH, a Takeda company, Vienna, Austria
2Shire US Inc., a Takeda company, Cambridge, MA
3Department of Gene Therapy and Regenerative Medicine, Free University of Brussels (VUB), Brussels, Belgium
4Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium

Introduction: Adeno-associated virus (AAV)–based factor IX (FIX) gene therapy has the potential to provide clinical benefit in patients with hemophilia B. TAK-748 is a novel next-generation AAV vector for FIX gene therapy. The vector design includes the insertion of 3 hepatocyte-specific cis-regulatory elements to increase the strength of the liver-specific transthyretin promoter driving expression of a human FIX transgene.

Aims: The objectives of this study were to investigate the TAK-748 dose-response relationship for FIX activity, and evaluate its efficacy, in FIX knockout (KO) mice and rhesus monkeys.

Methods: Male FIX KO mice (N=12/group) received single intravenous doses of TAK-748 (7.4×1010, 1.5×1011, 7.4×1011, or 1.5×1012 vector genomes [vg]/kg) or buffer. Blood samples were taken on days 7, 14, 28, 42, and 56 for the analysis of plasma FIX activity. At the end of the observation period, the bleeding phenotype was assessed by a tail-tip bleeding assay. The viral transduction efficiency of TAK‑748 in liver tissue was analyzed by quantitative real-time polymerase chain reaction. Safety assessments included monitoring for clinical signs, and histopathological analysis of selected organs (liver, spleen, kidney, and heart).

Male rhesus monkeys (N=3/group) were administered single TAK-748 intravenous bolus injections (3.8×1011, 9.5×1011, or 1.9×1012 vg/kg). Blood samples were collected before dosing and weekly after dosing up to week 18. Plasma FIX activity, human (hu)FIX antigen, and anti–hu-Padua FIX neutralizing antibodies were analyzed.

Results: No clinical signs or deaths were recorded in animals treated with TAK-748, and there were no TAK‑748–related histopathological findings in the tissues collected from the mice.

FIX activity levels in plasma from FIX KO mice treated with buffer were below the lower limit of quantification. Administration of TAK-748 resulted in a dose-dependent increase in mean plasma FIX activity, and supraphysiologic mean FIX levels up to 41.0 IU/mL (1.5×1012 vg/kg). In the tail-tip bleeding assay, blood loss was significantly reduced in the TAK-748 groups at dose levels above 7.4×1010 vg/kg (P<0.05 vs. buffer control).

Administration of TAK-748 to rhesus monkeys resulted in a dose-dependent increase in mean plasma FIX activity and antigen, and peak levels of huFIX expression were detected 2–4 weeks after treatment. Mean huFIX activity was 0.3, 0.6, and 1.9 IU/mL after treatment with 3.8×1011 vg/kg, 9.5×1011 vg/kg, and 1.9×1012 vg/kg TAK-748, respectively. A significant reduction in FIX activity and huFIX protein was observed in most of the animals starting about 4 weeks after dosing with TAK-748. In most animals, anti-huFIX Padua neutralizing antibody titers were detected at about week 6 of the study and correlated with the preceding reductions in huFIX expression.

Conclusions: Treatment with TAK-748 resulted in dose-dependent increases in plasma FIX activity and was efficacious in FIX KO mice and rhesus monkeys. There were no treatment‑related safety findings.

Disclosures: Weiller: Baxalta Innovations GmbH, a Takeda company: Employment. Wang: Shire US Inc., a Takeda company: Employment, Equity Ownership. Coulibaly: Baxalta Innovations GmbH, a Takeda company: Employment. Schuster: Baxalta Innovations GmbH, a Takeda company: Employment. Rottensteiner: Baxalta Innovations GmbH, a Takeda company: Employment, Equity Ownership. Sun: Shire US Inc., a Takeda company: Employment. Chuah: Shire, a Takeda company: Consultancy, Research Funding; Catalyst Bio: Consultancy, Research Funding; Pfizer: Research Funding. Vandendriessche: Shire, a Takeda company: Consultancy, Honoraria, Research Funding; Catalyst Bio: Consultancy, Research Funding; Pfizer: Research Funding; Biotest: Honoraria. Scheiflinger: Baxalta Innovations GmbH, a Takeda company: Employment, Equity Ownership. Höllriegl: Baxalta Innovations GmbH, a Takeda company: Employment, Equity Ownership.

*signifies non-member of ASH